Basic Research - Cancer(구연) Oral Session 3 / Basic Research - Cancer (Ⅱ) (O-025) Rm.201 10월 30일(수) 14:00-15:00 Anticancer Effect of Ginsenoside Rg3 and Rh2 in Renal Cell Carcinoma 한양대학교병원, ¹고려대학교 안암병원 윤영은, 이지영, 장은비, 문홍상, 천준¹, 박성열 Ginsenoside Rg3 and Rh2 have been known to inhibit cancer growth and metastasis. However, the anticancer effects of Rg3 and Rh2 in kidney cancers have not been evaluated. In this study, we investigate the anticancer effect of ginsenoside Rg3 and Rh2 on clear cell kidney cancer and the possible synergic effect of ginsenoside and mTOR inhibitor. We investigated the efficacy of Rg3 and Rh2 alone in human renal cell carcinoma cell lines (Caki-1, ACHN, A498). Cell viability was measured by CCK8 assay. To evaluate synergic effect of ginsenoside and mTOR inhibitor, everolimus was simultaneously treated with Rg3 or Rh2, followed by estimation of combination index to confirm the simultaneous treatment effect of the two substances. A fundamental pathway analysis was performed through cell cycle analysis and cDNA microarray. Ginsenoside Rg3 and Rh2 showed concentration-dependent inhibitory effects on Caki-1, ACHN, A498 cell growth in CCK8 assays. Everolimus also showed concentration-dependent anticancer effect on same cell lines. In combination treatment tests, Rg3 and everolimus showed synergic effects (CI 0.3 - 0.85), while combination of Rh2 and everolimus showed only additive effects. Gene expression alteration in the PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway and HIF-1 signaling pathway was analyzed in cDNA microarray. Ginsenoside Rg3 and Rh2 showed anticancer effect in ccRCC. Especially, ginsenoside Rg3 and everolimus showed strong synergic effect when treated in same time. These results suggest a new alternative to kidney cancer treatment. keywords : kidney cancer, ginsenoside,